A Genome-wide Association Study on the Endophenotype of Spatial Working Memory in ADHD
1 other identifier
observational
232
1 country
1
Brief Summary
Specific Aims:
- 1.To find the genetic variations associated with spatial working memory performance in patients with ADHD by using genome-wide association studies (GWAS);
- 2.To find the genetic variations associated with spatial working memory performance in healthy subjects by using GWAS;
- 3.To recruit a validation sample and to replicate the findings from the initial GWAS;
- 4.To test whether genetic variations significantly associated with spatial working memory are also associated with ADHD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2015
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2015
CompletedFirst Submitted
Initial submission to the registry
March 13, 2016
CompletedFirst Posted
Study publicly available on registry
March 17, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
July 31, 2018
CompletedSeptember 2, 2021
September 1, 2021
3 years
March 13, 2016
September 1, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Psychiatric interview
Subjects will be interviewed by Chinese Version of the Kiddie Epidemiologic version of the Schedule for Affective Disorders and Schizophrenia (K-SADS-E)
1 hour
Secondary Outcomes (1)
Spatial working memory
30 minutes
Study Arms (2)
ADHD group
Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
TD group
Typically development controls without lifetime diagnosis with ADHD
Eligibility Criteria
The existing sample is composed of 382 children withADHD and 150 healthy subjects. We plan to recruit additional 232 healthy subjects (104 in the first year; 128 in the second year), aged 7 to 18 years.
You may qualify if:
- Subjects without any current or lifetime DSM-IV psychiatric disorders based on the K-SADS-E interviews.
You may not qualify if:
- Participants who had any past or current medical or neurological illness, who currently took psychotropic medication, or whose intelligence quotient (IQ) score was less than 80 were excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Taiwan Univeristy Hospital
Taipei, Taiwan
Biospecimen
15 ml blood will be withdrawn from the subjects (one heparin-rinsed tube for cell culture, one EDTA rinsed tube for DNA extraction)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chi-Yung Shang, MD
Dept of Psychiatry, National Taiwan University Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 13, 2016
First Posted
March 17, 2016
Study Start
August 1, 2015
Primary Completion
July 31, 2018
Study Completion
July 31, 2018
Last Updated
September 2, 2021
Record last verified: 2021-09
Data Sharing
- IPD Sharing
- Will not share